Canadian Corporate News - [0] Landmark trial demonstrates that Diovan(R) (valsartan) significantly reduces combined all-cause mortality and morbidity in patients with heart, failure@…
Atacand
(candesartan, AstraZeneca)
Most Popular
10 Jobs That Pay $30 An Hour
5 Regular Mistakes In Public Speaking
Today’s Best Part-Time Jobs
3 Questions No Job Seeker Ever Wants To Be Asked?
13 Job Interview Mistakes To Avoid
An angiotensin receptor blocker (ARB) for treating patients with heart failure (NYHA class II-IV and an ejection fraction of 40% or less), to reduce the risk of death from cardiovascular causes and reduce hospitalizations for heart failure. Previously approved for hypertension. The second ARB approved for heart failure (HF); the first was Diovan (valsartan), approved in 2002 for a narrower indication, NYHA class II-IV heart failure in people who cannot tolerate ACE inhibitors. Under review at the Food and Drug Administration for use with an ACE …
Read the rest of this article with a Free Trial at HighBeam Research.
